Research programme: monoclonal antibodies - Regeneron

Drug Profile

Research programme: monoclonal antibodies - Regeneron

Alternative Names: REGN 3918; VelocImmune® research programme - Regeneron

Latest Information Update: 20 Apr 2017

Price : $50

At a glance

  • Originator Regeneron Pharmaceuticals
  • Class Monoclonal antibodies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer; Cardiovascular disorders; Eye disorders; Immunological disorders; Inflammation; Metabolic disorders; Musculoskeletal disorders; Pain

Most Recent Events

  • 20 Apr 2017 Regeneron Pharmaceuticals plans a phase I trial in Healthy Volunteers in USA (NCT03115996)
  • 02 Mar 2011 Preclinical development is ongoing in USA
  • 01 Apr 2009 Regeneron and The University of Texas Southwestern Medical Center enter into a strategic agreement to discover human monoclonal antibodies utilising VelocImmune® technology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top